Such persistent myths about innovation matter because they shape what leaders notice, fund, and permit. When innovation is equated with expensive technology, assigned to specialist teams, or judged only by whether a pilot succeeds, frontline problem-solving becomes easier to overlook and organizations learn less from both successful and unsuccessful attempts. Three myths are especially worth confronting.

Myth 1: Innovation requires a large budget. Frugal innovation shows that constraint can stimulate workable solutions rather than prevent them. Money still matters for evaluation and scale, but early innovation also depends on permission to test, relationships that support learning, and a Teal organization able to retain what staff discover.

Myth 2: Innovation is the job of innovators. Employee-driven innovation is distributed across organizations, not confined to innovation units or unusually “creative” individuals. Institutions that want these ideas to survive need protected opportunities for staff to improve work and a process for capturing useful changes before they disappear.

Myth 3: Failed innovation is a wasted effort. A pilot that falls short can still produce valuable knowledge if the organization examines why it failed and uses that learning in the next iteration. The important distinction is between failure that is ignored and failure that is analyzed. That requires enough psychological safety for staff to report what did not work.

If the myths above explain why innovation stalls, the next question is what allows it to take root and endure. The answer is not another innovation program, technology platform, or strategy document. It lies in the everyday institutional conditions that determine whether people can notice problems, respond to them, and carry useful changes beyond isolated individual effort. Three conditions recur across the organizational literature:

AI expands what health systems can attempt, from prediction and decision support to documentation and workflow automation. It also exposes institutional weaknesses quickly. High-stakes clinical AI depends on governed data, prepared workflows, people who understand changed roles, and processes for questioning or escalating unsafe output.

The Epic Sepsis Model shows why data governance must include independent validation rather than reliance on vendor-reported performance. At Michigan Medicine, independent external validation differed from that reported by the developer, whereby the model alerted on 18% of hospitalizations yet missed 67% of sepsis cases. Local data, calibration, alert burden, and monitoring are therefore part of governance, not postdeployment extras.

Duke Health’s Sepsis Watch illustrates the other side. Frontline clinicians helped design the workflow; trained rapid-response nurses; and reviewed alerts and communicated them to emergency physicians, who retained the decision to treat. Implementation required explicit roles, training, communication pathways, and trust, not simply a model placed into the electronic record. In lower-resource settings, the same principle applies: simpler tools still need infrastructure and workforce capacity proportionate to their risk.

Innovation does not always require institutional permission to begin, but it usually requires institutional support to last. None of this lowers the bar. Innovation is defined by the outcome it improves—including the restoration of clinician time and attention to the patient—not throughput alone nor by its cost or novelty. Stopping low-value practice is itself an innovation and often a more difficult one, because it removes visible activity rather than creating it. Four steps are practical:

The real institutional test is not how many pilots are launched or technologies are deployed, but whether useful ideas can become sustained improvements in care. AI will make technological activity increasingly easy to display; what will distinguish genuinely innovative organizations is their capacity to identify problems worth solving and enable staff to question and improve solutions, learn from evidence, and preserve what works.

In the AI era, the clearest divide between innovation and innovation theater may therefore be not the number of algorithms deployed, but whether an institution has built an ecosystem in which human creativity, critical judgment, and meaningful change can endure.